

Ref. No. JPL/CS/1641/2020

Date : 04<sup>th</sup> August, 2020

To  
BSE Ltd.  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001.

Sub.: **Outcome of Board Meeting held Today, i.e. 04<sup>th</sup> August, 2020 – Unaudited Financial Results for the Quarter ended 30<sup>th</sup> June, 2020.**

Reg.: **Regulation 30(2) and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.**

Dear Sir,

Kindly note that the Audit Committee have reviewed and the Board of directors of the Company have approved the unaudited financial results for the quarter ended on 30<sup>th</sup> June, 2020 during their respective meetings held today, i.e. on 4<sup>th</sup> August, 2020.


The unaudited financial results for the quarter from 1<sup>st</sup> April, 2020 to 30<sup>th</sup> June, 2020 duly signed in the format specified under regulation 33(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, is enclosed.

Also enclosed alongwith is the limited audit review report of the auditors of the Company, on the unaudited financial results for the quarter ended on 30<sup>th</sup> June, 2020.

Kindly take on record the above and acknowledge.

Thanking you,

Yours faithfully,  
For Jenburkt Pharmaceuticals Ltd.,



ASHISH R. SHAH  
Company Secretary and Compliance Officer

Encl.: As Stated Above.

 Science hai toh Hope hai  Hope hai toh Health hai  Health hai toh Happiness hai 



**Statement of Unaudited Standalone Financial Results for the Quarter Ended on 30/06/2020**

Rs. In Lacs other than EPS

Sr. No.	Particulars	Quarter Ended			Year Ended
		30-06-2020	31-03-2020	30-06-2019	31-03-2020
		Unaudited	Audited	Unaudited	Audited
1	Revenue from Operations	1743.12	3027.76	2083.74	11889.09
2	Other Income	97.59	128.70	123.80	421.83
3	Total income	1840.71	3156.46	2207.54	12310.92
4	Expenses				
	(a) Cost of Materials Consumed	133.73	221.86	239.98	965.21
	(b) Purchase of Stock-in-trade	475.11	427.45	644.05	2390.22
	(c) Changes in inventories of Finished Goods, Stock-in-trade and WIP	-183.70	89.81	-211.62	-48.74
	(d) Employee benefit expenses	810.10	947.92	882.29	3651.02
	(e) Finance Costs	11.15	12.14	6.74	52.56
	(f) Depreciation and Amortisation Expense	49.41	56.93	52.84	229.93
	(g) Other expenses	445.15	711.43	591.00	2956.94
	Total Expenses	1740.95	2467.54	2205.28	10197.14
5	Profit before exceptional items & Tax	99.76	688.92	2.26	2113.78
6	Exceptional Items	0.00	0.00	0.00	0.00
7	Profit before tax	99.76	688.92	2.26	2113.78
8	Tax Expense				
	(i) Current Tax	30.00	176.00	0.00	576.00
	(ii) Income Tax for previous years	8.51	12.10	0.00	13.89
	(ii) Deferred Tax	-39.55	39.17	-3.93	36.93
9	Profit after tax for the period	100.80	461.65	6.19	1486.96
10	Other Comprehensive Income				
	(i) Items that will not be reclassified to profit or loss	73.22	-234.29	9.41	-209.68
	(ii) Income Tax relating to Items that will not be reclassified to profit or loss	12.68	-27.16	19.18	-23.70
	(iii) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
	(iv) Income Tax relating to Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
11	Total Comprehensive Income for the period	186.70	200.20	34.78	1253.57
12	Paid up Equity Share Capital (F.V. Rs.10/- each)	458.94	458.94	458.94	458.94
13	Earnings Per Share (in Rs.) (F.V. Rs.10/-) Basic and Diluted	2.20	10.06	0.13	32.40

**Notes:**

- The above statement of unaudited standalone financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meeting held on 4th August, 2020.
- The Company is dealing exclusively in Pharmaceuticals business segment, hence segment wise reporting is not applicable.
- The figures of the previous year/period have been regrouped/rearranged to render them comparable with figures of the current period.

By order of the Board  
For Jenburkt Pharmaceuticals Ltd.



(DILIP H BHUTA)

WHOLE TIME DIRECTOR &amp; CFO

Place : Mumbai

Date : August 4, 2020

Science hai toh Hope hai Hope hai toh Health hai Health hai toh Happiness hai

# D.R.MEHTA & ASSOCIATES

(CHARTERED ACCOUNTANTS)

H-2, EVEREST BUILDING, 9<sup>TH</sup> FLOOR, TARDEO CIRCLE, MUMBAI - 400034

TEL: 23513758 / 23520330 FAX: 66607263, 9322508373

Email ID: [info@drmehta.in](mailto:info@drmehta.in), [vikram@drmehta.in](mailto:vikram@drmehta.in), [ashok@drmehta.in](mailto:ashok@drmehta.in)

Limited Review Report on Unaudited Quarterly Standalone Financial Results of **Jenburkt Pharmaceuticals Limited** under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015

To the Board of Directors of

Jenburkt Pharmaceuticals Limited

We have reviewed the accompanying statement of unaudited standalone financial results of JENBURKT PHARMACEUTICALS LTD for the quarter ended 30<sup>th</sup> June 2020 ('the statement').


This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For D.R.Mehta & Associates,  
Chartered Accountants  
(Firm Reg. No. 106207W)



Partner  
Ashok Mehta  
(Membership No. 101746)

UDIN: **20101746AAAABU9789**

Place: Mumbai

Date: August 4<sup>th</sup>, 2020.

